In Brief: Cardiometrics/Cordis
This article was originally published in The Gray Sheet
Cardiometrics/Cordis: Ink distribution agreement under which Johnson & Johnson subsidiary Cordis gains U.S. distribution rights to Cardiometrics' FloWire doppler guide wire. The pact broadens an existing agreement for marketing of the device overseas. Cardiometrics says J&J's "strong distribution channels should enable faster market penetration" in the U.S. Under the deal, J&J also gains U.S. rights to Cardiometrics' WaveWire pressure guide wire products. Cardiometrics submitted a 510(k) for WaveWire in December 1996. Cardiometrics, which recently entered an agreement to be acquired by intravascular ultrasound catheter firm EndoSonics ("The Gray Sheet" Feb. 3, p. 9), will continue to market its FloWire and WaveWire products domestically to "40 key accounts" through the end of 1997. At year-end, J&J, EndoSonics, and Cardiometrics will negotiate terms for 1998...
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.